Expert review of pharmacoeconomics & outcomes research
-
At present, health technology assessment (HTA) guidelines of many countries including Thailand have recommended EQ-5D as the preferred method for assessing utility. This study aims to generate an EQ-5D-5L value set based on societal preferences of Thai population. ⋯ Our study developed a Thai value set for EQ-5D using hybrid model. The findings from this study are of important to facilitate health technology assessment studies to inform policy decision-making as well as to promote the use of EQ-5D-5L in various health research in Thailand.
-
Expert Rev Pharmacoecon Outcomes Res · Aug 2018
Review Comparative StudyEconomic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. ⋯ While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.
-
Expert Rev Pharmacoecon Outcomes Res · Jun 2018
Comparative StudyCost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England.
To estimate the cost-effectiveness of Nasal High Flow (NHF) in the intensive care unit (ICU) compared with standard oxygen or non-invasive ventilation (NIV) from a UK NHS perspective. ⋯ For patients in ICU who are at risk of intubation or re-intubation, NHF cannula is likely to be cost-saving.
-
Expert Rev Pharmacoecon Outcomes Res · Dec 2017
ReviewOutcomes of transcatheter aortic valve replacement for bicuspid aortic stenosis - a systematic review of existing literature.
Patients with bicuspid aortic valve (BAV) have traditionally been excluded from large randomized clinical trials involving transcatheter aortic valve replacements (TAVR). Technical enhancements, availability of new generation devices and improved outcomes have led to a marked increase in TAVR volume across the world including off label use in patients with BAV stenosis. Areas covered: In this manuscript, we have reviewed the currently available data regarding safety, efficacy, and outcomes of TAVR in patients with BAV stenosis. 11 large observational studies with near 1300 patients with BAV stenosis were included to summarizes outcomes of TAVR. ⋯ New generation devices were associated with high device success rate whereas higher adverse procedural events were observed in early generation devices. There are no differences in post procedural outcomes with new generation TAVR devices for BAV when compared to tricuspid aortic anatomy. Larger studies are needed to evaluate the long-term outcome and durability of TAVR in patients with BAV.
-
Expert Rev Pharmacoecon Outcomes Res · Dec 2017
ReviewThe challenges of implementing pharmacogenomic testing in the clinic.
Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be addressed. Areas covered: In this expert review we discuss current challenges impacting the implementation of pharmacogenomic testing in the clinical practice. ⋯ Collaborative efforts among laboratories are needed to improve standardization of testing and reporting of the results. Clinicians need educational opportunities to improve understanding of which test to order and how to interpret the results. The electronic health records and other clinical systems need to improve their storage of the pharmacogenomics test results and interoperability to facilitate the use of clinically actionable results to improve patient care.